Neuromyelitis optica: it is time to move one step further
نویسندگان
چکیده
منابع مشابه
Neuromyelitis Optica
An 11-year-old girl developed sudden visual loss in her left eye, preceding subacute myelitis by 9 months. Multifocal lesions in the central nervous system were demonstrated by magnetic resonance imaging. Although unilateral blindness is unusual, the clinical findings predominantly involving the optic nerve and spinal cord were consistent with the diagnosis of neuromyelitis optica (NMO). This c...
متن کاملTreatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
BACKGROUND To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD). METHODS We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was ...
متن کاملIlluminating neuromyelitis optica pathogenesis.
W hat is the most important moment in the history of a disease? Let us consider neuromyelitis optica (NMO), which was coined by French neurologist Eugene Devic in 1894 for a disease believed until recently to be a subtype of multiple sclerosis (MS). The discovery (in 2004) of a disease-specific biomarker for NMO revolutionized our understanding of both NMO and MS (1). In PNAS, Hinson et al. (2)...
متن کاملNeuromyelitis optica of very late onset: one more case.
Dear editors, We read with extreme interest the paper by Souza et al.1 This study describes one case of a 75-year-old woman with neuromyelitis optica (NMO)1. Including this case, only six cases of neuromyelitis optica developing after the age of 70 have been reported. We think that it is important to describe our recent experience. A 72-year-old Caucasian woman sought our service complaining of...
متن کاملTreatment in Neuromyelitis Optica
Background: The effects of interferon1b (IFN1b ) administration in multiple sclerosis (MS) patients have been confirmed, however, those in neuromyelitis optica (NMO) patients have not been shown. In this study, we assessed the effects of IFN1b treatment on disease exacerbation and disability progression in MS or NMO patients. Methods: We reviewed a series of 104 consecutive patients with relaps...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos de Neuro-Psiquiatria
سال: 2017
ISSN: 0004-282X
DOI: 10.1590/0004-282x20170005